Day: March 10, 2026

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Written by Customer Service on March 10, 2026. Posted in Public Companies.

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD,...

SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 OverviewRevenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024. Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024. Gross profit rose 60.7% to $6.4 million...

Public Inc. Acquires Rocket Social Impact, Accelerating U.S. Growth and Expanding Integrated Social Impact Capabilities

Written by Customer Service on March 10, 2026. Posted in Mergers And Acquisitions.

New York and Toronto, March 10, 2026 (GLOBE NEWSWIRE) — Public Inc., a North American B Corp and creative social impact agency, today announced the acquisition of Rocket Social Impact, a U.S.-based advisory firm known for its impact strategy and delivery-focused work with nonprofit and corporate social impact organizations. The acquisition strengthens and expands Public’s U.S. footprint and deepens its ability to deliver integrated strategy and execution to purpose-driven clients across North America. “We continue to believe in the immense opportunity for purpose-driven organizations in the North American market right now,” said Phil Haid, CEO of Public Inc. “Organizations are under pressure to demonstrate real impact, not just intention, and our goal is to grow our presence in the U.S. Rocket brings disciplined, implementation-driven...

VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.

Written by Customer Service on March 10, 2026. Posted in Mergers And Acquisitions.

Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide eVTOL Commercialization FORT MILL, S.C., March 10, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) today announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, Inc. (“Flyte”) from Creatd, Inc. (OTCQB: CRTDD), resulting in 100% ownership of the AI-enabled regional aviation operator. The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the owner of a revenue-generating, asset-backed aviation platform with certified aircraft, tangible infrastructure, and scalable fleet economics. Full...

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 On track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs); regulatory update expected in 1H 2026 Expect to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 2H 2026 Completed oversubscribed $86 million public offering with participation from new and existing investors Cash, cash equivalents and investments of approximately...

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights. Three Months Ended December 31, Year Ended December 31, 2025 2025(in thousands, except ASP data) Revenue $ 16,631 $ 66,575 Gross margin 55.4 % 58.3 %Operating expenses $ 14,181 $ 52,869 Loss from operations $ (4,975 ) $ (14,070 )Net loss $ (4,673 ) $ (19,951 )Adjusted EBITDA $ (3,670 ) $ (9,794 )Cash, cash equivalents and restricted cash $32,420Trailing-twelve-month...

Core Molding Technologies Reports Full Year and Fourth Quarter 2025 Results

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

Fourth Quarter Total Sales Up 19.5% Driven by Elevated Tooling Revenue; Full Year Business Wins of $63 Million Support Multi-Year Revenue Expansion COLUMBUS, Ohio, March 10, 2026 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reported financial and operating results for the fiscal periods ended December 31, 2025. David Duvall, the Company’s President and Chief Executive Officer, said, “Fiscal 2025 was intensely focused on our Invest For Growth Must Win Battle – and we delivered as stated. We won $63 million in business,...

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company HighlightsThe IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis (AD) is ongoing at North American sites; the study began enrolling in mid-2025 with topline data expected in 2027. A recent blinded safety review showed a favorable emerging tolerability profile consistent with previous IMG-007 patient experience. The Company has submitted a protocol amendment intended to expand the number and exposure range of dosing regimens being evaluated, characterize the role of loading doses, evaluate patient-friendly dosing intervals, and understand the effect of short-...

Global Indemnity Group, LLC Reports Full Year 2025 Financial Results

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

Accident Year 2025 Underwriting Profitability Improves Across Every Quarter; Current Accident Year Combined Ratio Excluding California Wildfires Reaches 92.2% WILMINGTON, Del., March 10, 2026 (GLOBE NEWSWIRE) — Global Indemnity Group, LLC (Nasdaq: GBLI) (the “Company”) today reported financial results for the twelve months ended December 31, 2025. The year was defined by two distinct narratives: a significant California Wildfire loss event in January 2025, and a steady, quarter-by-quarter improvement in underlying underwriting performance that continued through year end. Net losses from the California Wildfires totaled $15.7 million pre-tax ($12.0 million after-tax). Excluding this event, the Company’s current accident year combined ratio improved in each successive period throughout 2025, reaching 92.2% for the...

LyondellBasell to address 2026 J.P. Morgan Industrials Conference

Written by Customer Service on March 10, 2026. Posted in Dividend Reports And Estimates.

HOUSTON and LONDON, March 10, 2026 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB), a leader in the global chemical industry, today announced that Agustin Izquierdo, executive vice president and chief financial officer, will participate in a fireside chat at the 2026 J.P. Morgan Industrials Conference in Washington, D.C., on Tuesday, March 17, 2026, at 3:40 p.m. EDT.Webcast and Presentation Slides AccessA live webcast can be accessed at the time of the event at https://investors.lyondellbasell.com/events-and-presentations/default.aspx. A replay of the event will be available at the same link within 24 hours following the webcast. About LyondellBasell  We are LyondellBasell (NYSE: LYB) – a leader in the global chemical industry creating solutions for everyday sustainable living. Through advanced technology and focused investments,...

Day: March 10, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals